Should clinicians use omalizumab for the treatment of nasal polyps?

Journal of Allergy and Clinical Immunology

Volumn 132, Issue 1, 2013, Pages 247-

  Naclerio, Robert M ^a   Baroody, Fuad M ^a   Pinto, Jayant M ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; LEUKOTRIENE; OMALIZUMAB; PREDNISONE; STEROID;

HUMAN; LETTER; NOSE POLYP; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SKIN TEST;

EID: 84882865109     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2013.04.001     Document Type: Letter

References (3)

1. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al. Omali-zumab is effective in allergic and nonallergic patients with nasal polyps and asthma. J Allergy Clin Immunol 2013;131:110-6.
2. Kern RC. Biologics and the treatment of chronic rhinosinusitis. J Allergy Clin Immunol 2013;131:117-8.
3. Pinto JM, Mehta N, DeTineo M, Wang J, Baroody FM, Naclerio RM. A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis. Rhinol-ogy 2010;48:318-24.